ZIM Laboratories Ltd

The formulation has been developed using the company's proprietary drug delivery technologies, combining naproxen delayed-release minitablets and esomeprazole pellets in a single hard gelatin capsule. Zim said the platform offers a differentiated, patient-friendly delivery system and forms part of its New Innovative Product (NIP) pipeline. The FDC is indicated for adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for reducing the risk of NSAID-associated gastric and duodenal ulcers. Zim Laboratories stated that the approval strengthens its presence in the pain-management and gastro-protective segments. The company has already signed a commercial supply agreement with an Indian pharmaceutical firm and is working toward launching the product in India in FY 2026'27 (FY27). Zim added that the approval aligns with its strategy of developing innovative, differentiated generics using advanced formulation technologies. ZIM Laboratories is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The company's consolidated net profit dropped 117.6% to Rs 0.42 crore as revenue fell 3.7% to Rs 88.71 crore in the quarter ended September 2025 as compared with the previous quarter ended September 2024. The scrip rose 0.45% to Rs 71.15 on the BSE. Powered by Capital Market - Live

Net loss of Zim Laboratories reported to Rs 0.42 crore in the quarter ended September 2025 as against net profit of Rs 2.38 crore during the previous quarter ended September 2024. Sales declined 3.72% to Rs 88.71 crore in the quarter ended September 2025 as against Rs 92.14 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales88.7192.14 -4 OPM %6.4910.34 - PBDT4.647.96 -42 PBT-0.342.96 PL NP-0.422.38 PL Powered by Capital Market - Live

Zim Laboratories will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live

Net loss of Zim Laboratories reported to Rs 1.87 crore in the quarter ended June 2025 as against net profit of Rs 0.90 crore during the previous quarter ended June 2024. Sales declined 12.30% to Rs 71.76 crore in the quarter ended June 2025 as against Rs 81.82 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales71.7681.82 -12 OPM %5.949.83 - PBDT2.436.18 -61 PBT-2.431.23 PL NP-1.870.90 PL Powered by Capital Market - Live

PSP Projects Ltd, BirlaNu Ltd, Kabra Extrusion Technik Ltd and Vishnu Chemicals Ltd are among the other losers in the BSE's 'B' group today, 04 August 2025.Zim Laboratories Ltd lost 19.98% to Rs 86.3 at 14:28 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 1.55 lakh shares were traded on the counter so far as against the average daily volumes of 14020 shares in the past one month.PSP Projects Ltd crashed 12.88% to Rs 661.7. The stock was the second biggest loser in 'B' group.On the BSE, 2.44 lakh shares were traded on the counter so far as against the average daily volumes of 5977 shares in the past one month.BirlaNu Ltd tumbled 11.26% to Rs 1979.45. The stock was the third biggest loser in 'B' group.On the BSE, 6240 shares were traded on the counter so far as against the average daily volumes of 739 shares in the past one month.Kabra Extrusion Technik Ltd pared 10.38% to Rs 260. The stock was the fourth biggest loser in 'B' group.On the BSE, 21920 shares were traded on the counter so far as against the average daily volumes of 7799 shares in the past one month.Vishnu Chemicals Ltd plummeted 9.74% to Rs 487.5. The stock was the fifth biggest loser in 'B' group.On the BSE, 55016 shares were traded on the counter so far as against the average daily volumes of 27317 shares in the past one month.Powered by Capital Market - Live

Zim Laboratories will hold a meeting of the Board of Directors of the Company on 7 August 2025.Powered by Capital Market - Live

Zim Laboratories announced that the 41th Annual General Meeting(AGM) of the company will be held on 27 June 2025.Powered by Capital Market - Live

Net profit of Zim Laboratories declined 39.68% to Rs 4.88 crore in the quarter ended March 2025 as against Rs 8.09 crore during the previous quarter ended March 2024. Sales declined 7.75% to Rs 108.73 crore in the quarter ended March 2025 as against Rs 117.86 crore during the previous quarter ended March 2024. For the full year,net profit declined 29.45% to Rs 12.17 crore in the year ended March 2025 as against Rs 17.25 crore during the previous year ended March 2024. Sales rose 3.16% to Rs 379.03 crore in the year ended March 2025 as against Rs 367.42 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales108.73117.86 -8 379.03367.42 3 OPM %13.4313.28 -11.5411.25 - PBDT13.4014.90 -10 38.1239.59 -4 PBT8.1111.00 -26 18.0123.64 -24 NP4.888.09 -40 12.1717.25 -29 Powered by Capital Market - Live

Zim Laboratories will hold a meeting of the Board of Directors of the Company on 20 May 2025.Powered by Capital Market - Live

Zim Laboratories (ZIM) has entered into a Dossier License, Product Supply, and Technology Know-How License Agreement with Globalpharma Co. (L.L.C.), a leading UAE-based pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments, one of the region's premier investment entities. This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs' proprietary Oral Thin Film technology platform, ThinOral'. Under the agreement, Globalpharma will register and commercialize 10 OTF-based Pharmaceutical and Nutraceutical products developed by ZIM, catering to regional patient needs with advanced, user-friendly dosage forms. Initially, ZIM Labs will supply bulk products while providing complete regulatory support for market registration in the UAE. Post-approval, ZIM will deliver ready-to-use powder mixes, enabling Globalpharma to undertake localized manufacturing and marketing of the finished formulations. Powered by Capital Market - Live